The depth of our bioavailability (BA) enhancement offering makes us a leader in addressing drug solubility and dissolution rate issues. We work collaboratively with our customers to advance compounds, or re-purpose existing compounds, across a full range of API properties and delivery challenges. Our end-to-end solutions incorporate full capabilities in bringing a compound from concept to commercialization, thereby minimizing program complexity, timelines and risk.
Industry estimates indicate that more than 80% of new chemical entities exhibit poor solubility or dissolution rate. Effectively addressing these patients is essential for advancing the compound and providing the desired therapeutic benefit of the drug product to patient. And ensuring that the solubility solution incorporates the ultimate manufacturability of the drug product can avoid time-consuming re-formulation and rapid advancement to market.
We recognize the core challenges of progressing the new chemical entities in today’s biopharmaceutical pipeline. That’s why we have developed a portfolio of technologies and services with which to address poor solubility and inadequate or inconsistent dissolution rate.